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Adequate responses by our innate immune system toward invad-
ing pathogens were of vital importance for surviving infections,
especially before the antibiotic era. Recently, a polymorphism in
Mal (Ser180Leu, TIRAP rs8177374), an important adaptor protein
downstream of the Toll-like receptor (TLR) 2 and 4 pathways, has
been described to provide protection against a broad range of
infectious pathogens. We assessed the functional effects of this
polymorphism in human experimental endotoxemia, and we dem-
onstrate that individuals bearing the TIRAP 180L allele display an
increased, innate immune response to TLR4 and TLR2 ligands, but
not to TLR9 stimulation. This phenotype has been related to an
increased resistance to infection. However, an overshoot in the
release of proinflammatory cytokines by TIRAP 180L homozygous
individuals suggests a scenario of balanced evolution. We have
also investigated the worldwide distribution of the Ser180Leu
polymorphism in 14 populations around the globe to correlate the
genetic makeup of TIRAP with the local infectious pressures. Based
on the immunological, clinical, and genetic data, we propose that
this mutation might have been selected in West Eurasia during the
early settlement of this region after the out-of-Africa migration of
modern Homo sapiens. This combination of functional and genetic
data provides unique insights to our understanding of the patho-
genesis of sepsis.
Innate immunity  TLR4  TLR2  evolution  cytokines
The nonsynonymous single nucleotide polymorphismSer180Leu (S180L) of the TIR domain-coding adaptor pro-
tein (TIRAP) gene, also known as adaptor protein Mal (1), was
found to be protective in heterozygous individuals for a broad
range of infectious diseases such as malaria, tuberculosis, bac-
teremia, and pneumococcal disease (1). Mal is involved in the
signaling pathways of Toll-like receptors (TLR) 2 and 4, which
are important innate immune receptors for the recognition of a
broad range of pathogenic Gram-negative and Gram-positive
bacteria (2). Recognition by TLRs eventually leads to activation
of NF-B and the transcription of proinflammatory genes that
activate the mechanisms of host defense and the clearance of the
pathogens. However, little is known about the in vivo functional
consequences of the S180L polymorphism or the possible dif-
ferences in the geographic distribution of the S180L polymor-
phism in relation to infectious pressure.
In this study we hypothesized that the difference in the
frequency of TIRAP 180L between the different geographical
regions was due to the effects of the mutation on the function of
TLR signaling, and was shaped by the pressure exerted by
different infections, either during the out-of-Africa migration of
early modern humans during the early Upper Paleolithic period
(60–40kya) (3) or the Neolithic demic expansion from the Near
East into Europe (10,000kya) (4, 5). This pressure may have
resulted in an increase of the frequency of TIRAP S180L
heterozygous individuals and thereby a strong rise of the fre-
quency of the TIRAP 180L allele in West-Eurasia populations.
Results and Discussion
In Vivo Models of Sepsis That Determine the Phenotypic Effect of the
S180L Genotype. Because of the high prevalence of the TIRAP
S180L polymorphism in the European population, we tested the
hypothesis that under severe bacterial pressure there is a patho-
physiological advantage that could favor selection of the TIRAP
180L allele variant. Therefore, we evaluated the functional
consequences of the heterozygous TIRAP S180L genotype dur-
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ing sepsis, a life-threatening infection accompanied by a systemic
inflammatory response (6). TLR4 is mainly involved in the
recognition of the lipopolysaccharide (LPS) of Gram-negative
bacteria (7), inducing intracellular signals through the adaptor
protein TIRAP/Mal (8). To avoid limitations of artifacts be-
tween in vitro and in vivo results, we determined the inflam-
matory phenotype in the most relevant in vivo model of sepsis:
that of experimental endotoxemia of human volunteers by i.v.
challenge with LPS.
Before and after exposure to LPS, blood was drawn at several
time points for proinflammatory (TNF, IFN-, IL-6) and anti-
inflammatory cytokine (IL-10) measurements. We found that,
compared with the normal homozygous TIRAP S180 individuals,
the heterozygous TIRAP S180L volunteers had a produced
significantly more proinflammatory cytokines after challenge
with LPS (Fig. 1 A–D). The higher in vivo production rate of
proinflammatory cytokines in individuals bearing the 180L allele
was accompanied by increased cytokine production when cells
isolated from these individuals were stimulated with the TLR2
ligand Pam3Cys, but not when they were stimulated with the
TLR9 ligand 35-cytidylylguanosine (CpG) DNA (Fig. 1E).
Although the cells isolated from the individuals bearing the 180L
did not release significantly more cytokines in vitro after LPS
stimulation, it is interesting to observe that the TIRAP 180L
homozygous individuals produced the highest amount of IL-6
after both Pam3Cys and LPS stimulation, but not after CpG
DNA. Both TLR2 and TLR4 signal through the TIRAP adaptor
molecule and therefore it is expected that the effect of the 180L
polymorphism should be observed in both. In contrast, TLR9
does not need the TIRAP adaptor molecule pathway and there-
fore showed no difference between the various TIRAP geno-
types. TIRAP-mediated signals are involved in LPS-induced
NF-B activation, but not for the IFN regulatory factor 3
(IRF3)-induced, type I IFN release. In line with the hypothesis
Fig. 1. Cytokine production capacity in individuals screened for the TIRAP S180L polymorphism. (A–D)Serum concentrations of proinflammatory cytokines
TNF, IFN-, IL-6 (A–C) and the anti-inflammatory cytokine IL-10 (D) after 2 ng/kg LPS injection. Concentrations are given as mean (pg/mL) and SD for TIRAP S180
homozygous (SS, n  14) and S180L heterozygous (SL, n  6) individuals. (E) To study the effect of the TIRAP 180L polymorphism on other TLRs, PBMCs were
stimulated with TLR2 (10 g/mL Pam3Cys), TLR4 (10 ng/mL LPS), and TLR9 (25 g/mL CpG) ligands. (F) IFN- release by PBMC of patients with or without
polymorphisms was also assessed. Concentrations are given as mean (pg/mL) and SEM for TIRAP S180 homozygous (SS, n  4), S180L heterozygous (SL, n  5)
individuals, and one 180L homozygous individual. *, P  0.05; **, P  0.01; ***, P  0.001 (Mann-Whitney U test).
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that type I IFN release would not be effected by the 180L TIRAP
allele, we found its production after cell stimulation with CpG
DNAwas not increased in individuals bearing this polymorphism
(Fig. 1F). LPS alone was not able to induce production of type
I IFN.
These data, clearly demonstrating an increased cytokine pro-
duction in primary cells of individuals bearing the S180L poly-
morphism, are in contrast to the functional in vitro analyses of
Khor et al. (1), based on transfection studies of the mutated
TIRAP allele, who reported diminished proinflammatory cyto-
kine induction in cells transfected with the mutated allele. It is
possible that endogenously expressed 180L modulates 180S in a
positive way, and that the transfection-based experiments do not
provide an accurate reflection of the in vivo data.
The increased cytokine production in individuals bearing the
TIRAP S180L genotype may have important consequences for
the susceptibility and severity of infections. It has been proposed
that individuals with relatively low cytokine production would be
protected against the effects of systemic inflammation. This idea
is based on the assumption that the high cytokine release during
sepsis is the cause of systemic inflammatory response syndrome
(SIRS), which ultimately leads to septic shock and death. Al-
though this may be the case for individuals already in a septic
state, it is unlikely to be true for the initial susceptibility to
infections. During the first stage of infections, the proinflam-
matory response of the host has to be strong and adequate for
a good clearance of the pathogenic microorganism (9, 10).
Therefore, a moderately increased cytokine release during the
primary stage of infection, as would be expected in heterozygous
S180L individuals, is likely beneficial for the outcome of the
infection, and the early clearance of bacteria prevents those
individuals from developing sepsis that could lead to SIRS.
However, if the cytokine release is reaching a certain threshold
leading to systemic inflammatory effects, which is suggested to
take place in homozygous 180L individuals, then this could
ultimately prove deleterious to the host and preclude the fixation
of the mutation in the population. This hypothesis is supported
by a study performed on 166 patients with Gram-negative
bacterial sepsis and ventilator-associated pneumonia (VAP).
Individuals homozygous for the 180L polymorphism had a
significantly more severe infection compared with the other
TIRAP genotypes (P  0.038 concerning clinical pulmonary
infection score) and a tendency toward a decreased oxygenation
of the tissues (Table 1).
Distribution of the TIRAP Polymorphism in Different Populations.We
determined the distribution of the TIRAP polymorphism fre-
quencies in 14 populations originating from Africa, West-
Eurasia, East-Eurasia, and the Americas (Fig. 2 and Table 2).
Distribution of the TIRAP S180 and 180L allele showed a high
frequency of 180L in West-Eurasian compared with African and
East-Asian populations (Fig. 1). To gain insight in the allelic
distribution of the TIRAP 180 polymorphism, all populations
were compared pairwise by using both an exact test for popu-
lation differentiation (11) and the Fst (12) statistics (Table 3).
Combining the population differentiation results with the Fst
test reveals that the populations are broadly divided according
to these 3 main geographic regions (Africa, East Eurasia, and
West Eurasia; see Table 2). The apparent difference in TIRAP
allelic frequencies within populations in Africa is most likely
caused by the low frequencies of the TIRAP 180L allele among
these populations (Table 2). Our data also revealed that the
highest frequencies of the TIRAP 180L allele is found in the
Middle-Eastern Bedouins from the Negev desert, which results
in the highest differentiation and dissimilarity with all other
studied populations. Two scenarios may explain this distribution
Table 1. Clinical characteristics of 160 patients with VAP and sepsis enrolled in the study
Characteristics SS SL LL
n (Male/female) 121 (91/30) 43 (31/12) 2 (2/0)
Age in years, mean  SD 61.4  18.1 55.9  12.2 48.5  27.6
CPIS, mean  SD* 7.76  1.11 7.74  1.31 9.50  0.70
SAPS II score, mean  SD 38.8  13.8 37.4  13.5 39.0  0
White blood cells per mL, mean  SD 13,312.1  7,013.4 12,809.8  4,921.8 10,030.1  5,600.3
Septic shock: no (%)† 65 (53.7) 25 (58.1) 1 (50?)
Septic shock: yes (%)† 56 (46.3) 18 (41.9) 1 (50)
pO2/FiO2, mean  SD 226.1  117.1 222.3  100.2 190.5  13.4
Polymorphismbetween genotypes are inHardy–Weinberg equilibrium. SS,wild type, i.e. patientswithoutMal
mutations; SL, mutant Mal, i.e. patients carrying the Ser180Leu SNP; LL, homozygous mutants, i.e., patines only
carrying the 180Leu SNP; CPIS, clinical pulmonary infection score. pO2/FiO2 ratios are given as an index of the
oxygentation.
*P  0.038 between WT and homozygotes; P  0.039 between heterozygotes and homozygotes (P values after
Bonferroni correction).
†Total numbers of patients in the subgroups comparing patients with and without septic shock. There were no
differences between groups.
Fig. 2. World distribution frequency of TIRAP S180 (gray) and 180L (black)
alleles among 14 populations. Populations of the African continent are Mali
(MA), Gambia (GA), Ghana (GH), and Kenya (KE). Eurasia populations are the
Bedouins (BE). European populations are Romania (RO), Basque (SP), the
Netherlands (NL), and United Kingdom (UK). Asian and New World popula-
tions are India (IN), Han Chinese (CH), Vietnam (VI), Papua New Guinea (PA),
and Trio Indians from Surinam (SU). The number of individuals of each
population is given in Table 1.
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of the mutation. In one of the scenarios, the mutation arose in
Africa, where it persisted in low prevalence after spreading due
to human migration in the Middle-East and Europe; and in the
other scenario, the mutation arose in West-Eurasia and was
brought back later in Africa through the gene transfer by the
European colonists. However, the high prevalence of the mu-
tation in the Middle-East and Europe suggests that if any
selection has influenced TIRAP 180L prevalence, it most likely
took place in the West-Eurasian region.
Dating the Selection on the 180L TIRAP Allele. The S180L TIRAP
polymorphism is conspicuously low in the African population
and absent in the Asian population. This similarity between the
African and East-Asian populations could indicate that the
selection on TIRAP 180L did not take place during the first
human Paleolithic migration out of Africa, because higher
frequencies of the TIRAP 180L allele would then also be
expected in Asia. Therefore, we tested the hypothesis that
selection on TIRAP 180L occurred during the more recent
Neolithic period when farming settlement of Europe took place
(1, 4, 5, 13). To test this, we performed an extended haplotype
homozygosity (EHH) test on the European panel from HapMap
(14). The EHH test, which can discern recent selection until a
maximum of 30,000 years (15, 16), revealed no statistically
significant difference (3 end borders, significance P  0.053; 5
end, P  0.438), indicating no strong recent selection on the
TIRAP 180L allele in the West-Eurasian population sample
(individuals with Northern and Western European ancestry).
Table 2. Frequencies of the TIRAP S180L polymorphism (SL) in all screened populations
Genotype Allele frequency Hardy-Weinberg
SS SL LL N S L Hom Het
Mali 64 2 0 66 0.985 0.015 64.02 1.98 0.992
Gambia 1237 15 0 1252 0.994 0.006 1237.08 14.92 0.978
Ghana 1094 1 0 1095 1.000 0.000 1094.00 1.00 1
Kenya 1877 68 0 1945 0.983 0.017 1887.85 57.15 0.735
Bedouins 35 48 14 97 0.608 0.392 50.53 46.47 0.931
Romania 75 20 3 98 0.867 0.133 74.60 23.40 0.534
Basque 68 39 3 110 0.795 0.205 74.04 35.96 0.64352
Netherlands 458 171 14 643 0.845 0.155 474.66 168.34 0.915
United Kingdom 944 350 35 1329 0.842 0.158 975.23 353.77 0.932
India 152 50 5 207 0.855 0.145 155.57 51.43 0.935
Han Chinese 87 1 0 88 0.994 0.006 87.00 1.00 0.999
Vietnamese 438 8 0 446 0.991 0.009 438.06 7.94 0.981
Papua 23 0 0 23 1.000 0.000 - - -
Surinam 97 0 0 97 1.000 0.000 - - -
OBS EXP
OBS, observed frequencies; EXP, expected frequency if populations would be in Hardy–Weinberg equilibrium (HW); Hom, homozygotes (SS and LL); Het,
heterozygotes (SL). P values for the HW represent values for the HW probability test. P  0.0035, corrected with the Bonferroni method, was considered
significant.
Table 3. Population differentiation test outcomes
United Han
Ghana Mali Gambia Kenya Bedouins India Romania Basque Netherlands Kingdom Chinese Vietnam
Mali 0.00744 - - - - - - - - - - -
Gambia 0.0041 0.0026 - - - - - - - - - -
Kenya 0.0105 -0.0039 0.0032 - - - - - - - - -
Bedouins 0.7942 0.32 0.7663 0.7369 - - - - - - - -
India 0.3411 0.0748 0.2976 0.2504 0.1565 - - - - - - -
Romania 0.4798 0.0826 0.379 0.2756 0.1488 -0.0038 - - - - - -
Basque 0.5764 0.1385 0.5136 0.4421 0.077 0.0094 0.0107 - - - - -
Netherlands 0.196 0.0715 0.1859 0.183 0.1601 -0.0012 -0.0018 0.0065 - - - -
United Kingdom 0.1447 0.0706 0.139 0.14 0.161 -0.0008 -0.0012 0.0055 -0.0005 - - -
Han Chinese 0.013 -0.002 -0.003 0.0001 0.3653 0.0949 0.1126 0.1716 0.0848 0.0822 - -
Vietnam 0.0116 -0.0023 -0.0001 0.0006 0.5941 0.1678 0.2219 0.3257 0.1153 0.0977 -0.0027 -
Surinam -0.0026 0.0124 0.0005 0.0052 0.3887 0.1073 0.1322 0.1912 0.0928 0.0891 0.0006 0.0024
Outcomes are presented in red if there was no significant differences (P  0.05) between the populations, meaning that the allelic compositions of the
populations do not differ. Outcomes are presented in green if the allelic composition differed (P 0.05 was considered to be significant). Numbers indicate the
pairwise Fst values between populations. Squares indicate populations that came from the same continent.
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Although this could indicate that the observed differences
between the populations of West-Eurasia and other continents
was the result of genetic drift, an alternative explanation is that
selection could also have taken place during the period between
the out-of-Africa migration [60–40 kya (3)] and the first suc-
cessful colonization of Europe [40–45 kya (3)]. This time scale
allows for recombination to have had enough time to make it
difficult to discover an evolutionary pressure by using the EHH
test (17). The hypothesis of an old ancestry of the mutation in
West-Eurasia is also supported by the presence of the mutation
in India, most likely due to the Indo-European origin of the
population tested. India clusters with other West-Eurasian pop-
ulations, rather than East-Asian neighbors.
With the use of HapMap (14), we investigated the distribution
pattern of the haplotype allele network of the TIRAP gene
between African, West-Eurasian, and East-Eurasian popula-
tions. Within these 3 HapMap populations, we detected 17
different haplotypes based on 12 polymorphisms (see Fig. 3 and
Table S1). Modeling established that Haplotype 3 is the ancient
haplotype of TIRAP, also to be found in the chimpanzee. Most
haplotypes form a star-like pattern around Haplotype 1, which
is a direct descendant of Haplotype 3. The exception is Haplo-
type 17, which is the only haplotype containing the TIRAP 180L
mutation. Haplotype 17 is closely linked to the ancient Haplo-
type 3, representing a different branching than the Haplotype 1
cluster (Fig. 3). In the HapMap database, no African individuals
with Haplotype 17 were found, although our own screening
revealed the presence of this haplotype in a small proportion of
the African individuals tested (Fig. 2 and Table 2). It is likely that
this is a result of recent genetic f low between the modern human
populations. This modeling shows that all haplotypes, with the
exception of Haplotype 17, are equally spread among the
different populations. The lack of the TIRAP 180L mutation
within the African HapMap database supports the scenario of
the origin of themutation in a population already located outside
of Africa.
Conclusion
These combined genotypic and phenotypic studies have shown
that a potent cytokine response, as a marker of an adequate
innate immune response, is associated with a lower susceptibility
to infections. Our findings form a link between this hypothesis
and support of the protective effects of heterozygosity for TIRAP
S180L reported by Khor and colleagues (1). Moreover, in an
evolutionary context this suggests that before the dispersal of
modern humans into Western Eurasia [40–45 kya (3)], those
individuals bearing the TIRAP S180L heterozygous phenotype
would have had greater resistance to infections in a harsh
environment. Furthermore, they would have been more likely to
survive should an infection become established. However, the
deleterious effects during severe sepsis in homozygous individ-
uals, due to even-higher proinflammatory cytokine production,
prevented fixation of this haplotype in the entire population.
In summary, our study confirms the finding that TIRAP S180L
heterozygous individuals have a distinctive phenotype compared
with the TIRAP S180 homozygous bearers, with the 180L allele
associated with a more pronounced inflammatory response and
a lower risk of developing septic shock. The frequency of the
TIRAP 180L allele is highly elevated in West-Eurasia, with
selection due to infectious pressure in this region being a likely
explanation. We could not confirm that this selection has taken
place recently during the Neolithic period from the Near East
into Europe. More likely, the selection of the advantageous
TIRAP variants that has shaped the West-Eurasian populations
has taken place during the early phase of the dispersal of modern
humans into West-Eurasia. Finally, the present study demon-
strates that, by determining the evolutionary path of genes
involved in the innate immune system, and complementing
genotype analysis with the functional phenotype, one can pro-
vide new insights in our understanding of the pathogenesis of
severe infections such as sepsis.
Materials and Methods
Human Endotoxemia Model. Twenty healthy volunteers were infused with
highly purified LPS at a dose of 2 mg/kg, as previously described (18). Before
and after 30, 60, 90, 120, 240, and 360 min, blood was collected and plasma
separated by centrifugation. Circulating concentrations of TNF, IL-6, IFN-,
and IL-10 were measured by specific LUMINEX kit (BioRad). Among the
volunteers, 14 were homozygote for the wild-type TIRAP allele, whereas 6
individuals were heterozygous for the TIRAP 180L allele.
Peripheral BloodMononuclear Cell (PBMC) Stimulation. PBMCswere isolated by
density gradient centrifugationonFicoll,washed3 times in coldRPMImedium
1640, counted, and resuspended in complete culture medium. PBMCs (final
concentration2.5106/mL)were stimulatedwithPam3Cys (10g/mL), LPS (10
ng/mL), or CpG DNA (25 g/mL) in 96-well, round-bottom plates for 24 h at
37 °C. After stimulation, supernatants were collected and directly used for
cytokine measurement.
Sepsis Patients.One-hundred-sixty-six patients were enrolled in a prospective
study conducted over the period of June 2004 to September 2005 at the
Department of Critical Care of the Evangelismos General Hospital and in the
2nd Department of Critical Care of the Attikon University Hospital of Athens,
Greece. The studywas approvedby the Ethics Committeeof bothhospitals. All
enrolled patients were intubated for at least 48 h before diagnosis of sepsis
and theywere all aged above 18 years. Exclusion criteria were the presence of
(i) neutropenia (500 neutrophils per mm3), (ii) HIV infection, and (iii) oral
intake of corticoids at a dose1mg/kg of equivalent prednisone for a period
greater than 1 month. Enrolled patients were followed-up for 28 days. Inclu-
sion criteria were the concomitant presence of (i) VAP and (ii) sepsis, severe
sepsis, or septic shock. The patients were selected based on infection with a
Gram-negativemicroorganism. Themost commonly culturedmicroorganisms
were Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneu-
moniae, and Enterobacter spp. Septic shock was defined as sepsis with sepsis-
induced hypotension requiring vasopressor therapy despite adequate fluid
challenge, along with the presence of hypoperfusion and organ dysfunction.
DNA Samples and TIRAP 180 Screening. DNA samples from the Han people
came from Corriell (Cat No. HD1000CHI). Other included populations are
described elsewhere (1, 19). Informed consent and written approval from the
relevant ethical review boards has been granted from all sample collections.
Frommost populations, bloodwas drawnand theDNAwas extractedby using
the isolation kit Puregene (Gentra Sytems). Genotyping of the Mal/TIRAP
S180L polymorphismwas performed by using TaqMan, SNPGenotypingAssay
Fig. 3. TIRAP gene allele haplotype network of the HapMap (14). Numbers
stand for thedifferent alleles, and letters betweeneach circle are thedifferent
polymorphisms included (see Table S1). Area of each circle correlates with the
amount of alleles.
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(Applied Biosystems). PCRs were set up according to the manufacturer’s
instructions. Thermal cyclingwas performed on a fast optical 96-well reaction
plate on the 7500 Fast Real-Time PCR system (Applied Biosystems) as follows:
Initial denaturation and enzyme activation at 95 °C for 10min, followed by 40
cycles of denaturation at 95 °C for 15 s, and annealing/extension at 60 °C for
1min.Mal SNP polymorphismwas determined by performing an Allelic Discrim-
ination Assay run on the 7500 Fast Real-Time PCR system (Applied Biosystems).
SNP polymorphism results were verified by using positive controls (20).
Statistics. The distributions between the TIRAP alleles in the different popu-
lations, theHardyWeinberg equilibrium, and Fstwerepreformedbymeans of
GENEPOP (21). The differentiation analysis is based on the unbiased estima-
tion of the P value of a log-likelihood-based (G) exact test, which is based on
the same principles as the Fisher exact test.
Cytokine and sepsis statistics were preformed by using the Statistical Pack-
age for the Social Sciences package, and differences were tested by the
Mann–Whitney U test. P  0.05 was considered to represent a statistically
significant difference.
As a neutrality test, we applied the EHH test (36) to the phased genotypic
information available from HapMap Data Rel. 21a/phaseII Jan 07, on NCBI
NB35 assembly, dbSNP b125. We used as the core haplotype that haplotype
formed by allele G at rs3802813 and allele A at rs3802814 as proxies for
rs8177374, which is absent in the phased haplotype display of this HapMap
release. As a summary statistic we used the extent for with the EHH for this
core haplotype was 1 in the HapMap Caucasian population within a genomic
region that extended 100 kb in each of the directions from the core. To test
whether thedistanceobservedwas longer thanexpectedunderneutrality,we
ran coalescent simulations that took into account the heterogeneity in re-
combination rates across these regions (obtained from the HapMap link) by
means of msHOT (22). We used demographic parameters reflecting the Out-
of-Africa model of human evolution by slightly modifying the model by
Schaffner et al. (23). Simulations were run for both 100kb downstream from
the core and for 100kb upstream from the core. The number of SNPs was
adjusted to that observed in the HapMap sample for that region. We added
3 filters to the neutral simulations: (i) We only considered those simulations
that resulted inanumberofdifferenthaplotypes equal to thatobserved in the
HapMap sample (as determinedby the core SNPs rs3802813 and rs3802814), in
the simulations the first 2 SNPs were considered the core set; (ii) in addition,
one of the simulated core haplotypes had to show a similar frequency to that
core haplotype under examination (obtained from the HapMap Caucasian
SNP information and defined by core SNPS, (allele G at rs3802813 and allele A
at rs3802814); (iii) the ancestral/derived states of the core SNPs in this prese-
lected, simulated haplotype had to also be identical to the ancestral/derived
states of the core SNPs at the core haplotype under examination. By compar-
ison with the orthologous genome regions of the Chimp and Rhesus Macaca,
rs3802813 ‘‘G’’ and rs3802814 ‘‘A’’were defined as ‘‘ancestral’’ and ‘‘derived’’,
respectively. Simulations satisfying these conditions were kept, but only the
information on the core haplotype was used for the EHH analysis. Finally, the
extent from the core SNPs for which EHHwas 1was recorded for the observed
HapMap data and this was tested against the distribution obtained from the
filtered simulations.
Network analysis was preformed by using the program Network 4.5.0.0
from Fluxus-engineering (http://www.fluxus-engineering.com) using the me-
dian joining methodology (24). For information regarding the composing of
the allele haplotypes and weighting of the different SNPs, see Table S1.
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